G.J. ConnellElsevier BVJournal of Cystic FibrosisMcGinnity T, Harms B, Trevellyan N, Connett GJ. Once daily long acting insulin achieves good glycaemic control in Cystic Fibrosis related diabetes (CFRD). J Cyst Fibros 2006;5:S62.
This randomized clinical trial examines the efficacy and safety of once-weekly icodec vs once-daily insulin degludec in people with insulin-naive type 2
Insulin glargine: A systematic review of a long-acting insulin analogue Background: Insulin glargine is the first long-acting basal insulin analogue indicated for subcutaneous administration once daily at bedtime in adults with... F Wang,JM Carabino,CM Vergara - 《Clinical Therapeutics》 被引量: ...
A novel, long-actinginsulin conjugate was developed by modificationwith a glycosaminoglycan (GAG; i.e., chondroitin [CH] or heparosan[HPN]) at different positions (GlyA1, LysB29, or both) via different linkers with varying arm lengths. The invitro glucose uptake-enhancing activity of conjugate...
Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-t... A Astrup,R Carraro,N Finer,... - 《International Journal of Obesity》 被引量: 749发表: 2012年 Liraglutide, a once-daily human GLP...
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus AimsTo assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus.MethodsThis parallel-grou...
Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1: 113–119. 33 Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, ...
Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapili...
We previously reported 26-week results of an industry-sponsored randomized trial in which researchers compared once-weekly subcutaneous exenatide ((Bydureon; 2 mg) and once-daily insulin glargine (Lantus) in 456 patients (mean age, 58) with longstanding type 2 diabetes. All were taking oral anti...
13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).This study revealed that the addition of once-weekly exenatide to insulin therapy for type 1 diabetes patients leads to significant improvements in A1C, body weight, body mass index and insulin doses....